Literature DB >> 2311224

Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease.

M Misaki1, T Shima, Y Yano, Y Sumita, U Kano, T Murata, S Watanabe, S Suzuki.   

Abstract

To assess the significance of serum basement membrane- and type III procollagen-related antigens in reflecting the degree of liver fibrosis, we measured radioimmunologically the concentrations of 7S collagen, laminin fragment P1, and the aminoterminal propeptide of type III procollagen (P-III-P) in serum from 48 patients with chronic viral liver disease: chronic persistent hepatitis (9), chronic active hepatitis (13), chronic active hepatitis with lobular disorganization (17), and liver cirrhosis (9). Concentrations of 7S collagen, laminin P1, and P-III-P in serum were increased in respectively 92%, 69%, and 77% of the patients with both chronic active hepatitis with lobular disorganization and liver cirrhosis. Concentrations of 7S collagen and laminin P1 in serum correlated well (r = 0.65, P less than 0.001, and r = 0.55, P less than 0.001, respectively) with the histological grade of liver fibrosis, whereas P-III-P correlated only weakly (r = 0.33, P less than 0.05). Evidently, measurement of serum 7S collagen is a reliable noninvasive test for detection of fibrosis in chronic viral liver disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311224

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide.

Authors:  C Hirayama; H Suzuki; A Takada; K Fujisawa; K Tanikawa; S Igarashi
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

2.  Noninvasive determination of liver collagen content in chronic hepatitis. Multivariate regression modeling with blood chemical parameters as variables.

Authors:  S Takamatsu; H Nakabayashi; Y Okamoto; H Nakano
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

3.  Non-invasive diagnosis of liver fibrosis.

Authors:  Hiroyasu Morikawa; Norifumi Kawada
Journal:  Clin J Gastroenterol       Date:  2011-07-31

4.  Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.

Authors:  D Y Lin; C M Chu; I S Sheen; Y F Liaw
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

5.  Correlation between stellate cell activation and serum fibrosis markers in choline-deficient L-amino acid-defined diet-induced rat liver fibrosis.

Authors:  K Hironaka; I Sakaida; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 6.  Hepatic fibrosis: are any of the serum markers useful?

Authors:  S Oh; N H Afdhal
Journal:  Curr Gastroenterol Rep       Date:  2001-02

Review 7.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

8.  Serum concentration of 7S collagen and prognosis in patients with the adult respiratory distress syndrome.

Authors:  M Kawamura; F Yamasawa; A Ishizaka; R Kato; K Kikuchi; K Kobayashi; T Aoki; F Sakamaki; N Hasegawa; T Kawashiro
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

Review 9.  Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

Authors:  Pamela Valva; Daniela A Ríos; Elena De Matteo; Maria V Preciado
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

10.  Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.

Authors:  Yasuhiro Matsue; Mikihiro Tsutsumi; Nobuhiko Hayashi; Takashi Saito; Mutsumi Tsuchishima; Nobuyuki Toshikuni; Tomiyasu Arisawa; Joseph George
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.